Since BRAF mutation is frequently observed in melanoma, BRAF inhibitors (BRAFi: dabrafenib, vemurafenib, and encorafenib) are now applied for clinical use, and show drastically higher clinical responses than dacarbazine-based treatments [13,14]. The gene discussed is BRAF; the disease is melanoma.